A rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure: A pilot study

Journal of the American College of Cardiology

Volumn 37, Issue 2, 2001, Pages 386-391

  Cheng, Van ^a   Kazanagra, Radmila ^a   Garcia, Alex ^a   Lenert, Leslie ^a,b   Krishnaswamy, Padma ^a   Gardetto, Nancy ^a   Clopton, Paul ^a   Maisel, Alan ^a,b,c  

^a VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN NATRIURETIC PEPTIDE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; HEART FAILURE; HEART LEFT VENTRICLE PRESSURE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ATRIAL NATRIURETIC FACTOR; CARDIOTONIC AGENTS; DIURETICS; DRUG THERAPY, COMBINATION; HEART FAILURE, CONGESTIVE; HUMANS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PATIENT ADMISSION; PILOT PROJECTS; POINT-OF-CARE SYSTEMS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; TREATMENT OUTCOME; VASODILATOR AGENTS;

EID: 0035137489     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(00)01157-8     Document Type: Article

References (46)

1. Recognition and management of patients with heart failure
2. Predictors of readmission among elderly survivors of admission with heart failure
3. Effect of DRGs on three-month readmission rate of geriatric patients with heart failure
4. Early readmission of elderly patients with heart failure
5. Post-hoc subgroup analysis and the truth of a clinical trial
6. Prospects for using a blood sample in the diagnosis of heart failure
7. Rapid transcriptional activation and early mRNA turnover of BNP in cardiocyte hypertrophy: Evidence for BNP as an "emergency" cardiac hormone against ventricular overload
8. Different secretion pattern of atrial natriuretic peptide and brain natriuretic peptide in patients with congestive heart failure
9. Molecular biology and biochemistry of the natriuretic peptide system
10. Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end-diastolic pressure in patients with symptomatic left ventricular dysfunction
11. Circulating levels of cardiac natriuretic peptides (ANP and BNP) measured by highly sensitive and specific immunoradiometric assays in normal subjects and in patients with different degrees of heart failure
12. Brain natriuretic peptide predicts mortality in the elderly
13. Adrenomedullin, endothelin, neuropeptide Y, atrial, brain and C-natriuretic prohormone peptides compared as early heart failure indicators
14. Plasma n-terminal probrain natriuretic peptide and adrenomedullin
15. Brain natriuretic peptide is stable in whole blood and can be measured using a simple rapid assay: Implications for clinical practice
16. Mechanisms and models of heart failure: A combinatorial approach
17. BNP: Increasing importance in the pathophysiology and diagnosis of congestive heart failure
18. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure: A substudy of the studies of left ventricular dysfunction (SOLVD)
19. Neuroendocrine activity in untreated heart failure
20. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality
21. Prognostic value of plasma intercellular adhesion molecule-1 and endothelin-1 concentration in patients with chronic congestive heart failure
22. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fraction and congestive heart failure
23. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure
24. Brain natriuretic peptide is stable in whole blood and can be measured using a simple rapid assay: Implications for clinical practice
25. An experimental study of cardiac natriuretic peptides as markers of development of CHF
26. BNP: Pathophysiological and potential therapeutic roles in acute congestive heart failure
27. Differential atrial and ventricular expression of myocardial BNP during evolution of heart failure: 46th Annual Scientific Session of the American College of Cardiology
28. High level of plasma BNP at discharge is an independent risk factor for mortality and morbidity in patients with congestive heart failure
29. Evaluation of plasma natriuretic peptides as markers for left ventricular dysfunction
30. Plasma brain natriuretic peptide is a marker for the prediction of progressive ventricular remodeling after acute myocardial infarction
31. Early risk stratification using cardiac troponin T and brain natriuretic peptide in patients with congestive heart failure
32. Natriuretic peptides: Physiology therapeutic potential and risk stratification in ischemic heart disease
33. Natriuretic peptides - Relevance in cardiac disease
34. Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: Prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction
35. ACC/AHA task force report: Guidelines for the evaluation and management of heart failure
36. A rapid bedside test for brain natriuretic peptide accurately predicts cardiac function in patients referred for echocardiography
37. Superiority of brain natriuretic peptide in assessing efficacy of therapy to improve symptoms of congestive heart failure in the outpatient setting
38. Cloning of cDNA encoding porcine brain natriuretic peptide
39. Cloning and sequence analysis of cDNA encoding - A precursor for human brain natriuretic peptide
40. Human and canine gene homologs of porcine brain natriuretic peptide
41. Natriuretic peptides - Relevance in cardiovascular disease
42. Rapid ventricular activation of brain natriuretic peptide gene expression in experimental acute myocardial infarction
43. Tailored treatment for heart failure: An emerging concept
44. Neurohumoral predictors of benefit from carvedilol in ischemic left ventricular dysfunction
45. Titration of vasodilator therapy in chronic heart failure according to plasma brain natriuretic peptide concentration: Randomized comparison of the hemodynamic and neuroendocrine effects of tailored versus empirical therapy
46. Treatment of heart failure guided by plasma amino terminal brain natriuretic peptide (N-BNP) concentrations